FR2820041A1 - Product used to improve photodynamic treatment of cancers contains luminophore that emits red light under X-ray excitation - Google Patents

Product used to improve photodynamic treatment of cancers contains luminophore that emits red light under X-ray excitation Download PDF

Info

Publication number
FR2820041A1
FR2820041A1 FR0101135A FR0101135A FR2820041A1 FR 2820041 A1 FR2820041 A1 FR 2820041A1 FR 0101135 A FR0101135 A FR 0101135A FR 0101135 A FR0101135 A FR 0101135A FR 2820041 A1 FR2820041 A1 FR 2820041A1
Authority
FR
France
Prior art keywords
red light
emits red
ray excitation
light under
product used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0101135A
Other languages
French (fr)
Other versions
FR2820041B3 (en
Inventor
Nero Didier Rege
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0101135A priority Critical patent/FR2820041B3/en
Publication of FR2820041A1 publication Critical patent/FR2820041A1/en
Application granted granted Critical
Publication of FR2820041B3 publication Critical patent/FR2820041B3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Product contains a luminophore that emits red light by the Campton effect under X-ray excitation. ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given in the source material.

Description

<Desc/Clms Page number 1> <Desc / Clms Page number 1>

La présente invention concerne une possibilité d'améliorer un traitement par thérapie photo dynamique (PDT). La thérapie photo dynamique consiste à stimuler par laser un produit photosensible, préalablement injecté dans les tissus atteints. Elle est utilisée en médecine pour soigner certains cancers. Une fois excité, le produit photosensible dégage une substance toxique pour les cellules malades. La stimulation par laser s'effectue quelques jours après l'injection par le biais d'une sonde dotée à son extrémité d'un laser rouge miniaturisé. Depuis 1990, la PDT a permis de découvrir deux produits photosensibles : le photofrin (marque déposée) et le benzoporphyrine . La limite actuelle de cette thérapie est la difficulté d'amener le laser rouge sur la partie à soigner d'où l'impossibilité de traiter des surfaces étendues vu les dimensions des sondes souples à fibre optique. Les produits utilisés doivent leur photosensibilité à la porphyrine, molécule complexe commune à la chlorophylle et à l'hémoglobine. De même que la chlorophylle absorbe les rayonnements violets et oranges-rouges du spectre solaire, réfléchissant les lumières vertes et jaunes lors de la photosynthèse, il réagit à la lumière rouge du laser. La présente invention consiste à joindre un produit luminophore au produit photosensible afin de rendre celui-ci réactif à une luminescence provoquée par rayons X. Les molécules susceptibles de diffuser des rayonnements électromagnétiques d'une longueur d'onde visible par effet CAMPTON sont : le sulfure de zinc, le platino-cyanure de baryum (lumière verte), le tungstène de baryum (lumière bleu). La plupart sont toxiques (ou cancérigène) et la longueur d'onde émise est assez éloignée du rouge. Si on garde les dérivés du platine et du tungstène et qu'on y associe des luminophores développés actuellement pour l'obtention du rouge en électronique (TV, laser, signalisation) tels que le gallium, l'europium etc., on doit atteindre le résultat espéré, exemple : le platino-fluorure de gallium (ou d'europium), le tungstène de gallium ou d'europium. Les molécules luminophores peuvent être dispersées sous forme de particules colloïdales dans un fluide le plus isotrope possible. Pour éviter un quelconque rejet, on peut utiliser comme milieu dispersant le plasma du malade, l'élimination des micelles, si nécessaire, sera réalisée par électrophorèse.  The present invention relates to a possibility of improving a treatment by dynamic photo therapy (PDT). Dynamic photo therapy consists in stimulating a photosensitive product, previously injected into the affected tissue, by laser. It is used in medicine to treat certain cancers. Once excited, the photosensitive product releases a toxic substance for diseased cells. The laser stimulation takes place a few days after the injection through a probe fitted at its end with a miniaturized red laser. Since 1990, PDT has enabled the discovery of two photosensitive products: photofrin (registered trademark) and benzoporphyrin. The current limit of this therapy is the difficulty of bringing the red laser to the part to be treated, hence the impossibility of treating large areas given the dimensions of the flexible fiber optic probes. The products used owe their photosensitivity to porphyrin, a complex molecule common to chlorophyll and hemoglobin. Just as chlorophyll absorbs purple and orange-red rays from the solar spectrum, reflecting green and yellow lights during photosynthesis, it reacts to red light from the laser. The present invention consists in joining a luminophore product to the photosensitive product in order to make the latter reactive to luminescence caused by X-rays. The molecules capable of diffusing electromagnetic radiation of a visible wavelength by CAMPTON effect are: sulfide zinc, barium platinum cyanide (green light), barium tungsten (blue light). Most are toxic (or carcinogenic) and the wavelength emitted is quite far from red. If we keep the platinum and tungsten derivatives and associate phosphors currently developed for obtaining red in electronics (TV, laser, signaling) such as gallium, europium etc., we must reach the expected result, for example: gallium (or europium) platinofluoride, gallium or europium tungsten. The phosphor molecules can be dispersed in the form of colloidal particles in the most isotropic fluid possible. To avoid any rejection, it is possible to use the patient's plasma dispersing medium, the removal of the micelles, if necessary, will be carried out by electrophoresis.

Le mode opératoire sera identique au procédé classique mise à part que le laser sera remplacé par l'émulsion colloïdale et l'exposition aux rayons X.The operating mode will be identical to the conventional method except that the laser will be replaced by the colloidal emulsion and exposure to X-rays.

Claims (3)

REVENDICATIONS 1) Produit pour améliorer un traitement par thérapie photo dynamique caractérisé en ce qu'il comprend un luminophore émettant des rayonnements d'une longueur d'onde proche du rouge par effet CAMPTON lorsqu'il est excité par des rayons X. 1) Product for improving a treatment by dynamic photo therapy, characterized in that it comprises a luminophore emitting radiation of a wavelength close to red by CAMPTON effect when it is excited by X-rays. 2) Produit selon la revendication 1 en ce que les molécules luminophores sont dispersées sous forme de particules colloïdales dans un fluide le plus isotrope possible.  2) Product according to claim 1 in that the phosphor molecules are dispersed in the form of colloidal particles in a fluid that is as isotropic as possible. 3) Produit selon l'une des revendications précédentes caractérisé en ce qu'il est choisi parmi le platino-fluorure de gallium, le platino-fluorure d'europium, le tungstène de gallium et le tungstène d'europium. 3) Product according to one of the preceding claims, characterized in that it is chosen from gallium platino-fluoride, europium platino-fluoride, gallium tungsten and europium tungsten.
FR0101135A 2001-01-29 2001-01-29 LUMINOPHORE PRODUCT FOR IMPROVING DYNAMIC PHOTO THERAPY AND AVOIDING SKIN PHOTOSENSITIZATION Expired - Lifetime FR2820041B3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0101135A FR2820041B3 (en) 2001-01-29 2001-01-29 LUMINOPHORE PRODUCT FOR IMPROVING DYNAMIC PHOTO THERAPY AND AVOIDING SKIN PHOTOSENSITIZATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0101135A FR2820041B3 (en) 2001-01-29 2001-01-29 LUMINOPHORE PRODUCT FOR IMPROVING DYNAMIC PHOTO THERAPY AND AVOIDING SKIN PHOTOSENSITIZATION

Publications (2)

Publication Number Publication Date
FR2820041A1 true FR2820041A1 (en) 2002-08-02
FR2820041B3 FR2820041B3 (en) 2003-04-11

Family

ID=8859321

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0101135A Expired - Lifetime FR2820041B3 (en) 2001-01-29 2001-01-29 LUMINOPHORE PRODUCT FOR IMPROVING DYNAMIC PHOTO THERAPY AND AVOIDING SKIN PHOTOSENSITIZATION

Country Status (1)

Country Link
FR (1) FR2820041B3 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2453860A (en) * 2007-10-18 2009-04-22 Searete Llc Ionising-radiation sensitive composition comprising luminescent and photosensitive materials
US8164074B2 (en) 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8168958B2 (en) 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
RU2606834C2 (en) * 2015-04-17 2017-01-10 Общество с ограниченной ответственностью "РЕВИКСАН" (ООО "РЕВИКСАН") Gel-photosensitizer for photodynamic therapy
US9557635B2 (en) 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2453860A (en) * 2007-10-18 2009-04-22 Searete Llc Ionising-radiation sensitive composition comprising luminescent and photosensitive materials
GB2453860B (en) * 2007-10-18 2011-03-16 Searete Llc Ionizing-radiation-responsive compositions,methods and systems
US8164074B2 (en) 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8168958B2 (en) 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US9557635B2 (en) 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems
RU2606834C2 (en) * 2015-04-17 2017-01-10 Общество с ограниченной ответственностью "РЕВИКСАН" (ООО "РЕВИКСАН") Gel-photosensitizer for photodynamic therapy

Also Published As

Publication number Publication date
FR2820041B3 (en) 2003-04-11

Similar Documents

Publication Publication Date Title
Li et al. Lanthanide‐doped near‐infrared nanoparticles for biophotonics
Tang et al. Near-infrared excited orthogonal emissive upconversion nanoparticles for imaging-guided on-demand therapy
Gu et al. In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles
Chen Nanoparticle self-lighting photodynamic therapy for cancer treatment
Choy et al. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research
M Scherer et al. New approaches to photodynamic therapy from types I, II and III to type IV using one or more photons
US20110238001A1 (en) Nanoparticle based photodynamic therapy and methods of making and using same
US20080286826A1 (en) Luminescent Particle and Method of Detecting a Biological Entity Using a Luminescent Particle
CN107722055B (en) Low-power white-light-driven mitochondrion-targeted fluorescent probe photosensitizer and synthesis method and application thereof
US20200133027A1 (en) Photo-biomodulation by endogenous auto-fluorescent compounds
Buchner et al. Photosensitiser functionalised luminescent upconverting nanoparticles for efficient photodynamic therapy of breast cancer cells
WO2017068252A1 (en) Particle comprising at least one ferrimagnetic or ferromagnetic iron oxide nanoparticle associated with at least one compound for medical or cosmetic use
Li et al. AIE-nanoparticle assisted ultra-deep three-photon microscopy in the in vivo mouse brain under 1300 nm excitation
Feng et al. Förster resonance energy transfer properties of a new type of near-infrared excitation PDT photosensitizer: CuInS 2/ZnS quantum dots-5-aminolevulinic acid conjugates
Valanciunaite et al. Complex of water-soluble CdSe/ZnS quantum dots and chlorin e6: interaction and FRET
CN106668859B (en) A kind of photosensitive drug and preparation method thereof to faint photaesthesia
Shi et al. Upconversion core/shell nanoparticles with lowered surface quenching for fluorescence detection of Hg 2+ ions
Elsherbiny et al. Green synthesis of broccoli-derived carbon quantum dots as effective photosensitizers for the PDT effect testified in the model of mutant Caenorhabditis elegans
FR2820041A1 (en) Product used to improve photodynamic treatment of cancers contains luminophore that emits red light under X-ray excitation
Tavakkoli et al. Effect of LaF3: Ag fluorescent nanoparticles on photodynamic efficiency and cytotoxicity of Protoporphyrin IX photosensitizer
Zhou et al. Quantum yield measurements of photochemical reaction-based afterglow luminescence materials
Hu et al. Squaraine dye-sensitized upconversion with enhanced stability and minimized aggregation-caused quenching
US6233481B1 (en) Diagnostic application of sono-chemical excitation of fluorescent photosensitizers
Morozova et al. Photodiagnosis and photodynamic effects of bacteriochlorin-naphthalimide conjugates on tumor cells and mouse model
Li et al. Hypocrellin B doped and pH-responsive silica nanoparticles for photodynamic therapy